Integration enables streamlined access to Zepbound at reduced prices through LillyDirect, serving 75,000+ weight management patients with expanded dosing options.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.

LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.

Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million. Paid off all outstanding debt during the quarter. Subsequent to quarter end, fully

LifeMD (Nasdaq: LFMD) announced a lower cash-pay price for GLP-1 medications Wegovy and Ozempic as part of its collaboration with Novo Nordisk. LifeMD will offer the 0.25 mg and 0.5 mg doses at $199 per month for two fills for new patients, which the company describes as the lowest cash-pay pricing nationwide.The drugs are offered through the LifeMD Weight Management Program, which includes virtual consultations, diagnostic testing, secure messaging, and lifestyle education. LifeMD cited a strategic shift from compounded GLP-1s to direct manufacturer partnerships to align with regulatory and reimbursement trends and to scale virtual obesity and metabolic care.

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects

LifeMD (Nasdaq: LFMD) sold its majority ownership interest in WorkSimpli Software LLC in a transaction that values WorkSimpli at an approximately $65 million enterprise value. The deal closed on November 4, 2025, and LifeMD received about $22 million cash at closing, representing 91.6% of the $24.0 million base purchase price attributable to the 80% interest sold. Sellers are eligible for up to an additional $28.0 million in cash tied to growth and operational targets over the next three years.LifeMD said it expects to use existing NOLs to offset most capital gains and will reallocate resources to expand its virtual care and pharmacy offerings, including cardiometabolic care beginning in H1 2026 and continued scaling of Rex MD and e-pharmacy products.

LifeMD (NASDAQ:LFMD) has expanded its collaboration with Novo Nordisk to offer Ozempic® at $499 per month to eligible self-pay patients through its virtual care platform. The offering targets uninsured patients and those whose insurance doesn't cover GLP-1 therapies.Through integration with NovoCare® Pharmacy, patients can access all FDA-approved dose strengths of Ozempic® and Wegovy® within LifeMD's comprehensive care platform, which includes virtual consultations, clinical support, diagnostic testing, and pharmacy coordination. The platform also provides access to Lilly's Zepbound® through integration with LillyDirect pharmacy provider.Ozempic® is FDA-approved for type 2 diabetes, which affects approximately 36 million Americans. This collaboration aims to improve accessibility to authentic, FDA-approved GLP-1 treatments at competitive self-pay prices.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, reported strong Q2 2025 financial results with total revenue increasing 23% year-over-year to $62.2 million. The company's telehealth segment showed impressive growth, with revenue up 30% to $48.6 million and adjusted EBITDA surging 560% to $3.4 million.Key operational highlights include reaching 297,000 active telehealth subscribers, launching a nationwide behavioral health offering, and acquiring a virtual women's health brand. The company generated over $8 million in operating cash flow and exited the quarter with $36.2 million in cash, having fully repaid all senior debt.However, LifeMD revised its full-year 2025 guidance downward due to temporary challenges in its Rex MD business, now expecting total revenue of $250-255 million and adjusted EBITDA of $27-29 million, compared to previous guidance of $268-275 million and $31-33 million respectively.

Virtual healthcare leader expands C-suite with operations veteran Webb Dray as COO, while elevating marketing and analytics leadership. See strategic moves.

LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.

Telehealth revenue soars 70% to $52.4M with first-ever profitable quarter. See how LifeMD's GLP-1 partnerships and Medicare expansion fuel record growth. Get insights.

New virtual health platform combines hormone optimization, bone health, and wellness services. Insurance-covered care launches Summer 2025. See expansion details.

New Medicare coverage expands LifeMD's virtual care to 21M+ beneficiaries across 26 states. Includes weight management programs. See growth potential.

LifeMD (NASDAQ: LFMD) reported strong Q4 2024 financial results with consolidated revenues increasing 43% year-over-year to $64.3 million, driven by a 60% growth in telehealth revenue. The company achieved record quarterly adjusted EBITDA of $9.0 million, up 78% year-over-year.Key highlights include telehealth adjusted EBITDA increasing 396% to $5.9 million, telehealth active subscribers growing 27% to 275,000, and WorkSimpli subscribers rising 3% to 164,000. The company ended 2024 with over $35 million in cash and improved full-year cash flow from operations by 99% to $17.5 million.For 2025, LifeMD provided guidance of $265-275 million in consolidated revenue and $30-32 million in consolidated adjusted EBITDA. The company plans to launch Medicare services on April 1 and is preparing to introduce virtual-first behavioral health and women's health specialty offerings later in the year.